Journal Scans
MO19390 (SAiL): Bleeding Events in a Phase IV Study of First-Line Bevacizumab With Chemotherapy in Patients With Advanced Non-Squamous NSCLC
Incidence of Bevacizumab-Related Bleeding Events in NSCLC
E Dansin, S Cinieri, P Garrido, M Kohlhaeufl, et al
20120009
2012 Jan 9
Lung Cancer
MO19390 (SAiL): Bleeding Events in a Phase IV Study of First-Line Bevacizumab With Chemotherapy in Patients With Advanced Non-Squamous NSCLC
Lung Cancer. 2012 Jan 9;[Epub Ahead of Print], E Dansin, S Cinieri, P Garrido, M Kohlhaeufl, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Introduction: The clinical benefit and safety profile associated with first-line bevacizumab with doublet chemotherapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC) was established in two large phase III studies, E4599 and AVAiL. SAiL, a single-arm phase IV study, was conducted to evaluate bevacizumab with a range of first-line chemotherapy regimens in a routine oncology practice setting.Methods: This analysis of the SAiL data was undertaken to specifically evaluate bleeding...
